APA (7th ed.) Citation

CA, R., J, J., A, S., K, G., & P, O. (2023). Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study. Human vaccines & immunotherapeutics, 19(1), 2160600. https://doi.org/10.1080/21645515.2022.2160600

Chicago Style (17th ed.) Citation

CA, Robertson, Jacqmein J, Selmani A, Galarza K, and Oster P. "Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster to Adults Aged ≥59 Years: A Phase III Randomized Study." Human Vaccines & Immunotherapeutics 19, no. 1 (2023): 2160600. https://doi.org/10.1080/21645515.2022.2160600.

MLA (9th ed.) Citation

CA, Robertson, et al. "Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster to Adults Aged ≥59 Years: A Phase III Randomized Study." Human Vaccines & Immunotherapeutics, vol. 19, no. 1, 2023, p. 2160600, https://doi.org/10.1080/21645515.2022.2160600.